1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Gastrointestinal Stromal Tumor (GIST)-Pipeline Insights, 2016

Gastrointestinal Stromal Tumor (GIST)-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Gastrointestinal Stromal Tumor (GIST)-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Gastrointestinal Stromal Tumor (GIST). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Gastrointestinal Stromal Tumor (GIST). DelveInsight’s Report also assesses the Gastrointestinal Stromal Tumor (GIST) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Gastrointestinal Stromal Tumor (GIST)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Gastrointestinal Stromal Tumor (GIST) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Gastrointestinal Stromal Tumor (GIST)-Pipeline Insights, 2016

Illustrative Table of contents

- Gastrointestinal Stromal Tumor (GIST) Overview
- Gastrointestinal Stromal Tumor (GIST) Pipeline Therapeutics
- Gastrointestinal Stromal Tumor (GIST) Therapeutics under Development by Companies
- Gastrointestinal Stromal Tumor (GIST) Filed and Phase III Products
- Comparative Analysis
- Gastrointestinal Stromal Tumor (GIST) Phase II Products
- Comparative Analysis
- Gastrointestinal Stromal Tumor (GIST) Phase I and IND Filed Products
- Comparative Analysis
- Gastrointestinal Stromal Tumor (GIST) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
- Gastrointestinal Stromal Tumor (GIST) - Dormant Products
- Companies Involved in Therapeutics Development for Gastrointestinal Stromal Tumor (GIST)
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Gastrointestinal Stromal Tumor (GIST) Assessment by Monotherapy Products
- Gastrointestinal Stromal Tumor (GIST) Assessment by Combination Products
- Gastrointestinal Stromal Tumor (GIST) Assessment by Route of Administration
- Gastrointestinal Stromal Tumor (GIST) Assessment by Stage and Route of Administration
- Gastrointestinal Stromal Tumor (GIST) Assessment by Molecule Type
- Gastrointestinal Stromal Tumor (GIST) Assessment by Stage and Molecule Type
- Gastrointestinal Stromal Tumor (GIST) Therapeutics - Discontinued Products
- Gastrointestinal Stromal Tumor (GIST) Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Gastrointestinal Stromal Tumor (GIST) Assessment by Monotherapy Products
- Gastrointestinal Stromal Tumor (GIST) Assessment by Combination Products
- Gastrointestinal Stromal Tumor (GIST) Assessment by Route of Administration
- Gastrointestinal Stromal Tumor (GIST) Assessment by Stage and Route of Administration
- Gastrointestinal Stromal Tumor (GIST) Assessment by Molecule Type
- Gastrointestinal Stromal Tumor (GIST) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.